Andrew K Cheng

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

Bonaventura Clotet, A. LaMarca, B. Clotet, 2012, The Lancet. Infectious diseases.

Systemic and Renal Pharmacokinetics of Adefovir and Tenofovir Upon Coadministration

Ramin Ebrahimi, R. Ebrahimi, B. Kearney, 2005, Journal of clinical pharmacology.

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Joel E Gallant, Edwin DeJesus, Schlomo Staszewski, 2004, JAMA.

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Joel E Gallant, Edwin DeJesus, B. Gazzard, 2006, The New England journal of medicine.